Work

First clinical and immunogenicity results including all subjects enrolled in a phase I study of Nous-209, an off-the-shelf immunotherapy, with pembrolizumab, for the treatment of tumors with a deficiency in mismatch repair/microsatellite instability (dMMR/MSI).

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.2515

Authors: Marwan Fakih, Dung T. Le, Katrina Sophia Pedersen, Anthony Frank Shields, Manish A. Shah, Sarbajit Mukherjee, Patricia Delaite, Théa Faivre, Anna Morena D'Alise, Guido Leoni, Gabriella Cotugno, Francesca Langone, Elisa Scarselli, Michael J. Overman

Institutions: City Of Hope National Medical Center, Johns Hopkins University, Wayne State University, The Barbara Ann Karmanos Cancer Institute, Weill Cornell Medicine, Roswell Park Comprehensive Cancer Center, Nouscom (Italy), The University of Texas MD Anderson Cancer Center

Language: English

Topic: Immunotherapy and Immune Responses

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4281741968

Cites:

Cited by: 8

Related to: 10